Clinical Trial Search

Primary: Determination of the Prevalence of R5 and X4-tropic Variants of HIV in HIV-infected Population in Russia — 123; 85; 114; 78 participants

Primary: Tolerability and Safety of the Treatment. — 0; 0 participants

Primary: Substudies 01, 02 and 03: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical…

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Vaccine Regimen — 16; 18; 16; 7 Participants

Primary: Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — -8605.8; -100719.8; -3406.5 Copies per milliliter

Primary: The Number of Subjects With Treatment Related Adverse Events — 2; 1; 2 Participants

Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants

Primary: Number of Participants Reporting Local Reactogenicity Events Signs and Symptoms: Pain and/or Tenderness — 5; 4; 1; 6 Participants

Primary: HIV Viral Load — -0.18; -0.05; 0.002; 0.26 HIV RNA copies/mL — p=0.008

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration — 7; 6; 0; 3 Participants

Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 participants

Primary: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) — -1.17; -2.15; -2.31; -0.28 Copies per milliliter…

Primary: Number of Participants With Severe and Life-threatening Adverse Events (AEs) — 0; 4; 4; 0 Participants

Primary: Number of Participants With Treatment-Emerging Adverse Events — 1; 1; 4; 3 Participants

Primary: Change in the Number of Conserved Elements (CEs) With a CD4 or a CD8 T Cell Response From Week 0 to Week 26 — 0; 0; 0 Number of CEs — p=0.137

Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 812; 794; 805; 1599 Participants

Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio

Primary: Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine. — 2 participants with Grade 3 events related

Primary: Evaluation of the Safety of MVA HIV-B at Week 2 in Arm 1 — 22 Participants

Primary: Grade 3 and Serious Adverse Events — 0 Participants

Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants

Primary: Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24 — 80; 69; 76; 72 Percentage of Participants

Primary: Incidence Rate of HIV-1 Infection Diagnosed After Enrollment (Concurrent With First Vaccination) Through 24 Months After Enrollment — 0.034; 0.033; 0.034; 0.033 events…

Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened

Primary: Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD) — 0.00; 0.00; 0.00; 0.10 Proportion of participants — p=0.48

Primary: Number of Subjects With Anti-V1V2 Total Immunoglobulin G (IgG) Binding Antibody Multiplex Assay (BAMA) Response Call — 25; 15; 8; 20 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 5; 7; 6; 8 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants

Primary: Part 1:Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) — 3; 2; 4; 3 Participants